{"id":788088,"date":"2023-10-04T11:54:07","date_gmt":"2023-10-04T15:54:07","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/femasys-inc-to-showcase-femaseed-at-the-annual-meeting-of-the-american-society-of-reproductive-medicine\/"},"modified":"2023-10-04T11:54:07","modified_gmt":"2023-10-04T15:54:07","slug":"femasys-inc-to-showcase-femaseed-at-the-annual-meeting-of-the-american-society-of-reproductive-medicine","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/femasys-inc-to-showcase-femaseed-at-the-annual-meeting-of-the-american-society-of-reproductive-medicine\/","title":{"rendered":"Femasys Inc. to Showcase FemaSeed at the Annual Meeting of the American Society of Reproductive Medicine"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">ATLANTA, Oct.  04, 2023  (GLOBE NEWSWIRE) &#8212; Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office, accessible solutions, including a lead late-clinical stage product candidate and innovative diagnostic products, today announced that it will be exhibiting at the annual meeting of the American Society of Reproductive Medicine (ASRM): \u201cThe Past, The Present, and The Pipeline\u201d, being held in New Orleans, Louisiana from October 14-18, 2023.<\/p>\n<p>Femasys will be showcasing its reproductive portfolio, including FemaSeed<sup><em>\u00ae<\/em><\/sup>, an innovative infertility treatment designed to deliver sperm directly to where conception occurs in a woman\u2019s fallopian tube that recently received 510(k) clearance from the United States Food and Drug Administration (FDA) allowing for U.S. commercialization last month, and our complimentary diagnostic products FemVue<em><sup>\u00ae<\/sup><\/em>, the first FDA-cleared product that enables a safe, reliable and real-time evaluation of the fallopian tubes and FemCath<sup><em>\u00ae<\/em><\/sup>, the first FDA-cleared product that allows for selective evaluation of a fallopian tube with contrast.<\/p>\n<p>Femasys will be at booth # 937 at ASRM.<\/p>\n<p>Femasys is creating accessible, innovative options for women, as exemplified by its now FDA-cleared product, FemaSeed<sup><em>\u00ae<\/em><\/sup>\u00a0for infertility treatment (also approved in Canada), as well as its lead product candidate, FemBloc<sup><em>\u00ae<\/em><\/sup>\u00a0in late-stage clinical development for permanent birth control. The Company is commercializing complementary diagnostic products that were internally developed through its in-house manufacturing capabilities, with regulatory approvals in the U.S., Canada, and other ex-U.S. territories.<\/p>\n<p>\n        <strong>About the American Society for Reproductive Medicine and ASRM 2023 Meeting<\/strong>\n      <\/p>\n<p>The American Society for Reproductive Medicine (ASRM) is dedicated to the advancement of the science and practice of reproductive medicine. The Society accomplishes its mission through the pursuit of excellence in evidence-based, life-long education and learning, through the advancement and support of innovative research, through the development and dissemination of the highest ethical and quality standards in patient care, and through advocacy on behalf of physicians and affiliated healthcare providers and their patients.<\/p>\n<p>At ASRM 2023, multi-disciplinary professionals will discover the latest in topics including reproductive endocrinology and infertility, basic science, genetics, male reproduction, access to care, mental health, and practice management.<\/p>\n<p align=\"justify\">\n        <strong>About FemaSeed<sup>\u00ae<\/sup><\/strong>\n      <\/p>\n<p>FemaSeed is an innovative infertility treatment designed to deliver sperm to the fallopian tube where conception occurs. It is intended to enhance natural fertilization and provide a first-line treatment option for infertility. FemaSeed is less invasive and more affordable than assisted reproduction procedures, such as in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI). Femasys is supporting an ongoing pivotal clinical trial specific for male factor infertility. FemaSeed has achieved U.S. FDA clearance and regulatory approval in Canada.<\/p>\n<p>\n        <strong>About Femasys <\/strong>\n      <\/p>\n<p>Femasys is a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office, accessible solutions, including a lead revolutionary late-clinical stage product candidate and FDA-cleared, innovative therapeutic and diagnostic products. Femasys\u2019 FemBloc<sup>\u00ae<\/sup>\u00a0permanent birth control in late-stage clinical development is the first and only non-surgical, in-office, permanent birth control method intended to be a safer option for women at substantially less cost than the long-standing surgical alternative. Femasys\u2019 FemaSeed<sup>\u00ae<\/sup>\u00a0Intratubal Insemination, an innovative infertility treatment designed to deliver sperm directly where conception occurs, is now FDA-cleared and has received regulatory approval in Canada. The Company has developed diagnostic products that are complementary for which it has achieved regulatory approvals to market in the U.S., Canada, and other ex-U.S. territories, and which are commercial-ready due to its in-house manufacturing capabilities. The Company\u2019s diagnostic products include FemVue<sup>\u00ae<\/sup>\u00a0for fallopian tube assessment by ultrasound, which can be used in conjunction with FemCath<sup>\u00ae<\/sup>, an intrauterine catheter for selective fallopian tube evaluation, and FemCerv<sup>\u00ae<\/sup>, an endocervical tissue sampler for cervical cancer diagnosis. Learn more at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=hJn7Kh6CvboJagUegMsoS1oyYPtOHeGCj6QtpYleyHq02DbJyTShURlRUvZMzD3oveG7Hi8jqL4KUdT_W4787A==\" rel=\"nofollow noopener\" target=\"_blank\">www.femasys.com<\/a>, or follow us on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=YueB8mwGuuVCuUZ3ufhREQgrISZn4hhEYPDxLrhdmF3GZUK3A1pL1HceqyR0hesmwry-iKbOkjS3jxJpK_tObg==\" rel=\"nofollow noopener\" target=\"_blank\">X<\/a>, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zP7D11Lj1LsDW7piJ7GggC1Lj40tN-vBGMYaKaSZwMPEbEctVBuJoTfbDpGFirxabGsn6ii-TNSMQrorkOYnXWD14dsn6TcuNyk86dGSgis=\" rel=\"nofollow noopener\" target=\"_blank\">Facebook<\/a> and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=HAbrnfNIc8T3ftey3GLO3T_5gbALQk6upZD18eFC3h5gOoSh8ha5nDJuSbwK-ljNvXr9ZBwLXKwzXpq7xJ9UWbDe0fXzl2BzFutNf3VvmGA=\" rel=\"nofollow noopener\" target=\"_blank\">LinkedIn<\/a>.<\/p>\n<p>\n        <strong>Forward-Looking Statements\u00a0<\/strong>\n      <\/p>\n<p>\n        <em>This press release contains forward-looking statements that are subject to substantial risks and uncertainties. Forward-looking statements can be identified by terms such as \u201cmay,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201cexpect,\u201d \u201cplan,\u201d \u201canticipate,\u201d \u201ccould,\u201d \u201cpending,\u201d \u201cintend,\u201d \u201cbelieve,\u201d \u201cpotential,\u201d \u201chope,\u201d or \u201ccontinue\u201d or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on our current expectations and are subject to inherent uncertainties, risks and assumptions, many of which are beyond our control, difficult to predict and could cause actual results to differ materially from what we expect. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate.\u00a0Factors that could cause actual results to differ include, among others: our ability to develop and advance our current product candidates and programs into, and successfully initiate, enroll and complete, clinical trials; the ability of our clinical trials to demonstrate safety and effectiveness of our product candidates and other positive results; estimates regarding the total addressable market for our product candidates; our business model and strategic plans for our products, technologies and business, including our implementation thereof; and those other risks and uncertainties described in the section titled &#8220;Risk Factors&#8221; in our Annual Report on Form 10-K for the year ended December 31, 2022 and other reports as filed with the SEC. Forward-looking statements contained in this press release are made as of this date, and Femasys undertakes no duty to update such information except as required under applicable law.\u00a0<\/em>\n      <\/p>\n<p>\n        <strong>Contacts:\u00a0<\/strong>\n      <\/p>\n<p>\n        <strong>Investors\u00a0<\/strong><br \/>\n        <br \/>Chuck Padala\u00a0<br \/>LifeSci Advisors, LLC\u00a0<br \/>917-741-7792\u00a0<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=f_M_s3vge1iXNY1fy5mPohKXwrfIDCTHWQ1kZQ1KQ-r-dxZX1Cocv6BOt6AjZNHWHdOovJJzbtDWgpy1vaD3yXPDBulJoMMHrStrY5uePeS7BJ_ZHVmuX--NNJA2XS07\" rel=\"nofollow noopener\" target=\"_blank\">chuck@lifesciadvisors.com<\/a><\/p>\n<p>\n        <strong>Femasys Inc.\u00a0<\/strong><br \/>\n        <br \/>Investor Contact:\u00a0<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=pEFpEX7_s31oSqTOTub4RkZNjCdL5XJm8nm5QUbBL4rjJWa7QTTbOPoFoA6swmfZ8-pQ_elYg_EBe_tMCh_q5g==\" rel=\"nofollow noopener\" target=\"_blank\">IR@femasys.com<\/a><\/p>\n<p>Media Contact:\u00a0<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=7aJp6wxyr2gX2eS4uDqIXTtENnYJI0o1iQIlvFcBz8fLgxB_H6d5WUkKBbZ_SHbDgV0vOejjsb-MZKck8LoucKmqkvLLY9XX6TzOvIQo-Ts=\" rel=\"nofollow noopener\" target=\"_blank\">Media@femasys.com<\/a><\/p>\n<p \/>\n      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODk0MzIyNiM1ODU1Nzc3IzIwMjg4MTM=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/NDcyNjQxNTYtMWU5Ni00NDYwLTk2ODEtMzgzZDQ0NjNhMzJjLTEwNDAzODQ=\/tiny\/Femasys-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>ATLANTA, Oct. 04, 2023 (GLOBE NEWSWIRE) &#8212; Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office, accessible solutions, including a lead late-clinical stage product candidate and innovative diagnostic products, today announced that it will be exhibiting at the annual meeting of the American Society of Reproductive Medicine (ASRM): \u201cThe Past, The Present, and The Pipeline\u201d, being held in New Orleans, Louisiana from October 14-18, 2023. Femasys will be showcasing its reproductive portfolio, including FemaSeed\u00ae, an innovative infertility treatment designed to deliver sperm directly to where conception occurs in a woman\u2019s fallopian tube that recently received 510(k) clearance from the United States Food and Drug Administration (FDA) allowing &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/femasys-inc-to-showcase-femaseed-at-the-annual-meeting-of-the-american-society-of-reproductive-medicine\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Femasys Inc. to Showcase FemaSeed at the Annual Meeting of the American Society of Reproductive Medicine&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-788088","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Femasys Inc. to Showcase FemaSeed at the Annual Meeting of the American Society of Reproductive Medicine - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/femasys-inc-to-showcase-femaseed-at-the-annual-meeting-of-the-american-society-of-reproductive-medicine\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Femasys Inc. to Showcase FemaSeed at the Annual Meeting of the American Society of Reproductive Medicine - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"ATLANTA, Oct. 04, 2023 (GLOBE NEWSWIRE) &#8212; Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office, accessible solutions, including a lead late-clinical stage product candidate and innovative diagnostic products, today announced that it will be exhibiting at the annual meeting of the American Society of Reproductive Medicine (ASRM): \u201cThe Past, The Present, and The Pipeline\u201d, being held in New Orleans, Louisiana from October 14-18, 2023. Femasys will be showcasing its reproductive portfolio, including FemaSeed\u00ae, an innovative infertility treatment designed to deliver sperm directly to where conception occurs in a woman\u2019s fallopian tube that recently received 510(k) clearance from the United States Food and Drug Administration (FDA) allowing &hellip; Continue reading &quot;Femasys Inc. to Showcase FemaSeed at the Annual Meeting of the American Society of Reproductive Medicine&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/femasys-inc-to-showcase-femaseed-at-the-annual-meeting-of-the-american-society-of-reproductive-medicine\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-10-04T15:54:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODk0MzIyNiM1ODU1Nzc3IzIwMjg4MTM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/femasys-inc-to-showcase-femaseed-at-the-annual-meeting-of-the-american-society-of-reproductive-medicine\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/femasys-inc-to-showcase-femaseed-at-the-annual-meeting-of-the-american-society-of-reproductive-medicine\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Femasys Inc. to Showcase FemaSeed at the Annual Meeting of the American Society of Reproductive Medicine\",\"datePublished\":\"2023-10-04T15:54:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/femasys-inc-to-showcase-femaseed-at-the-annual-meeting-of-the-american-society-of-reproductive-medicine\\\/\"},\"wordCount\":916,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/femasys-inc-to-showcase-femaseed-at-the-annual-meeting-of-the-american-society-of-reproductive-medicine\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODk0MzIyNiM1ODU1Nzc3IzIwMjg4MTM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/femasys-inc-to-showcase-femaseed-at-the-annual-meeting-of-the-american-society-of-reproductive-medicine\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/femasys-inc-to-showcase-femaseed-at-the-annual-meeting-of-the-american-society-of-reproductive-medicine\\\/\",\"name\":\"Femasys Inc. to Showcase FemaSeed at the Annual Meeting of the American Society of Reproductive Medicine - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/femasys-inc-to-showcase-femaseed-at-the-annual-meeting-of-the-american-society-of-reproductive-medicine\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/femasys-inc-to-showcase-femaseed-at-the-annual-meeting-of-the-american-society-of-reproductive-medicine\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODk0MzIyNiM1ODU1Nzc3IzIwMjg4MTM=\",\"datePublished\":\"2023-10-04T15:54:07+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/femasys-inc-to-showcase-femaseed-at-the-annual-meeting-of-the-american-society-of-reproductive-medicine\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/femasys-inc-to-showcase-femaseed-at-the-annual-meeting-of-the-american-society-of-reproductive-medicine\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/femasys-inc-to-showcase-femaseed-at-the-annual-meeting-of-the-american-society-of-reproductive-medicine\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODk0MzIyNiM1ODU1Nzc3IzIwMjg4MTM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODk0MzIyNiM1ODU1Nzc3IzIwMjg4MTM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/femasys-inc-to-showcase-femaseed-at-the-annual-meeting-of-the-american-society-of-reproductive-medicine\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Femasys Inc. to Showcase FemaSeed at the Annual Meeting of the American Society of Reproductive Medicine\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Femasys Inc. to Showcase FemaSeed at the Annual Meeting of the American Society of Reproductive Medicine - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/femasys-inc-to-showcase-femaseed-at-the-annual-meeting-of-the-american-society-of-reproductive-medicine\/","og_locale":"en_US","og_type":"article","og_title":"Femasys Inc. to Showcase FemaSeed at the Annual Meeting of the American Society of Reproductive Medicine - Market Newsdesk","og_description":"ATLANTA, Oct. 04, 2023 (GLOBE NEWSWIRE) &#8212; Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office, accessible solutions, including a lead late-clinical stage product candidate and innovative diagnostic products, today announced that it will be exhibiting at the annual meeting of the American Society of Reproductive Medicine (ASRM): \u201cThe Past, The Present, and The Pipeline\u201d, being held in New Orleans, Louisiana from October 14-18, 2023. Femasys will be showcasing its reproductive portfolio, including FemaSeed\u00ae, an innovative infertility treatment designed to deliver sperm directly to where conception occurs in a woman\u2019s fallopian tube that recently received 510(k) clearance from the United States Food and Drug Administration (FDA) allowing &hellip; Continue reading \"Femasys Inc. to Showcase FemaSeed at the Annual Meeting of the American Society of Reproductive Medicine\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/femasys-inc-to-showcase-femaseed-at-the-annual-meeting-of-the-american-society-of-reproductive-medicine\/","og_site_name":"Market Newsdesk","article_published_time":"2023-10-04T15:54:07+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODk0MzIyNiM1ODU1Nzc3IzIwMjg4MTM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/femasys-inc-to-showcase-femaseed-at-the-annual-meeting-of-the-american-society-of-reproductive-medicine\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/femasys-inc-to-showcase-femaseed-at-the-annual-meeting-of-the-american-society-of-reproductive-medicine\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Femasys Inc. to Showcase FemaSeed at the Annual Meeting of the American Society of Reproductive Medicine","datePublished":"2023-10-04T15:54:07+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/femasys-inc-to-showcase-femaseed-at-the-annual-meeting-of-the-american-society-of-reproductive-medicine\/"},"wordCount":916,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/femasys-inc-to-showcase-femaseed-at-the-annual-meeting-of-the-american-society-of-reproductive-medicine\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODk0MzIyNiM1ODU1Nzc3IzIwMjg4MTM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/femasys-inc-to-showcase-femaseed-at-the-annual-meeting-of-the-american-society-of-reproductive-medicine\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/femasys-inc-to-showcase-femaseed-at-the-annual-meeting-of-the-american-society-of-reproductive-medicine\/","name":"Femasys Inc. to Showcase FemaSeed at the Annual Meeting of the American Society of Reproductive Medicine - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/femasys-inc-to-showcase-femaseed-at-the-annual-meeting-of-the-american-society-of-reproductive-medicine\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/femasys-inc-to-showcase-femaseed-at-the-annual-meeting-of-the-american-society-of-reproductive-medicine\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODk0MzIyNiM1ODU1Nzc3IzIwMjg4MTM=","datePublished":"2023-10-04T15:54:07+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/femasys-inc-to-showcase-femaseed-at-the-annual-meeting-of-the-american-society-of-reproductive-medicine\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/femasys-inc-to-showcase-femaseed-at-the-annual-meeting-of-the-american-society-of-reproductive-medicine\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/femasys-inc-to-showcase-femaseed-at-the-annual-meeting-of-the-american-society-of-reproductive-medicine\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODk0MzIyNiM1ODU1Nzc3IzIwMjg4MTM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODk0MzIyNiM1ODU1Nzc3IzIwMjg4MTM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/femasys-inc-to-showcase-femaseed-at-the-annual-meeting-of-the-american-society-of-reproductive-medicine\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Femasys Inc. to Showcase FemaSeed at the Annual Meeting of the American Society of Reproductive Medicine"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/788088","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=788088"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/788088\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=788088"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=788088"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=788088"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}